CA2483875A1 - 6,11 bicyclic erythromycin derivatives - Google Patents

6,11 bicyclic erythromycin derivatives Download PDF

Info

Publication number
CA2483875A1
CA2483875A1 CA002483875A CA2483875A CA2483875A1 CA 2483875 A1 CA2483875 A1 CA 2483875A1 CA 002483875 A CA002483875 A CA 002483875A CA 2483875 A CA2483875 A CA 2483875A CA 2483875 A1 CA2483875 A1 CA 2483875A1
Authority
CA
Canada
Prior art keywords
present
compounds
subject
erythromycin derivatives
invention further
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002483875A
Other languages
French (fr)
Other versions
CA2483875C (en
Inventor
Yat Sun Or
Guoqiang Wang
Ly Tam Phan
Deqiang Niu
Yao-Ling Qiu
Nha Huu Vo
Jay Judson Farmer
Ying Hou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enanta Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from US10/436,622 external-priority patent/US7129221B2/en
Publication of CA2483875A1 publication Critical patent/CA2483875A1/en
Application granted granted Critical
Publication of CA2483875C publication Critical patent/CA2483875C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
The invention further includes process by which to make the compounds of the present invention.
CA002483875A 2002-05-13 2003-05-13 6,11 bicyclic erythromycin derivatives Expired - Fee Related CA2483875C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14439602A 2002-05-13 2002-05-13
US10/144,396 2002-05-13
US10/436,622 2003-05-13
PCT/US2003/014914 WO2003095466A1 (en) 2002-05-13 2003-05-13 6,11 bicyclic erythromycin derivatives
US10/436,622 US7129221B2 (en) 2002-05-13 2003-05-13 6,11-bicyclic erythromycin derivatives

Publications (2)

Publication Number Publication Date
CA2483875A1 true CA2483875A1 (en) 2003-11-20
CA2483875C CA2483875C (en) 2008-09-23

Family

ID=29418515

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002483875A Expired - Fee Related CA2483875C (en) 2002-05-13 2003-05-13 6,11 bicyclic erythromycin derivatives

Country Status (3)

Country Link
AU (1) AU2003229037B8 (en)
CA (1) CA2483875C (en)
WO (1) WO2003095466A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910558B2 (en) 2002-05-13 2011-03-22 Enanta Pharmaceuticals, Inc. Bridged macrocyclic compounds and processes for the preparation thereof
US7022679B2 (en) 2002-05-13 2006-04-04 Enanta Pharmaceuticals, Inc. Processes for the preparation of 6-11 bicyclic erythromycin derivatives
US7135573B2 (en) 2002-05-13 2006-11-14 Enanta Pharmaceuticals, Inc. Processes for the preparation of O-(6-Pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine
WO2005028493A1 (en) * 2003-09-12 2005-03-31 Chiron Corporation Antimicrobial derivatives
US7414030B2 (en) 2004-01-07 2008-08-19 Enanta Pharmaceuticals, Inc. 6-11 Bicyclic erythromycin derivatives
CN1910171B (en) * 2004-01-14 2011-09-28 伊南塔医药品股份有限公司 Method for preparation of 6-11 bicyclo erythromycin derivant
WO2005080408A1 (en) * 2004-01-23 2005-09-01 Enanta Pharmaceuticals, Inc. Bridged macrocyclic compounds and processes for the preparation thereof
US7384921B2 (en) 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
KR100924610B1 (en) 2004-12-07 2009-11-02 이난타 파마슈티칼스, 인코포레이티드 3,6-bicyclolides
US7229972B2 (en) 2004-12-07 2007-06-12 Enanta Pharmaceuticals, Inc. 3,6-Bicyclolides
TW200635600A (en) 2004-12-13 2006-10-16 Enanta Pharm Inc Tetracyclic bicyclolides
WO2006065721A2 (en) 2004-12-13 2006-06-22 Enanta Pharmaceuticals, Inc. 11, 12-lactone bicyclolides
US7384922B2 (en) 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
BRPI0610477A2 (en) * 2005-05-04 2010-06-22 Enanta Pharm Inc compound, pharmaceutical composition comprising the same, method of treating a bacterial infection, inflammation and cystic fibrosis in a patient in need thereof
US7589067B2 (en) 2005-10-12 2009-09-15 Enanta Pharmaceuticals, Inc. 6, 11-bridged tricyclic macrolides
US7407942B2 (en) 2006-03-29 2008-08-05 Emata Pharmaceuticals, Inc 3,6-bridged 9,12-oxolides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR015986A1 (en) * 1997-10-29 2001-05-30 Abbott Lab ERYTHROMYCIN DERIVATIVES BRIDGED IN 6.11, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURES FOR THEIR PREPARATION
US6046171A (en) * 1997-10-29 2000-04-04 Abbott Laboratories 6,11-bridged erythromycin derivatives

Also Published As

Publication number Publication date
CA2483875C (en) 2008-09-23
AU2003229037A1 (en) 2003-11-11
AU2003229037B8 (en) 2009-07-02
AU2003229037B2 (en) 2007-01-18
WO2003095466A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
TWI327573B (en) 6-11 bicyclic ketolide derivatives
WO2004062601A3 (en) Antibacterial agents
WO2005000863A3 (en) 6, 11-4c-bicyclic 9a-azalide derivatives
WO2006063039A3 (en) 3, 6-bicyclolides
WO2004087728A3 (en) 6,11-3c-bicyclic 9a-azalide derivatives
UA94901C2 (en) Antibacterial piperidine derivatives
WO2005070113A3 (en) 9n-substituted 6-11 bicyclic erythromycin derivatives
EP2662353A3 (en) Antibacterial agents
YU11699A (en) 6-substituted ketolydes having a bactericidal impact, procedures for the production thereof and their pharmaceutical preparations
CA2483875A1 (en) 6,11 bicyclic erythromycin derivatives
WO2006039263A3 (en) NOVEL BICYCLIC 9a-AZALIDE DERIVATIVES
CA2292359A1 (en) Novel azalides and methods of making same
WO2004096823A3 (en) Novel ketolide derivatives
WO2003004509A3 (en) C12 modified erythromycin macrolides and ketolides having antibacterial activity
CA2349338A1 (en) Novel macrolide antibiotics
WO2006065721A3 (en) 11, 12-lactone bicyclolides
WO2004096822A3 (en) Pyridyl substituted ketolide antibiotics
WO2009075923A3 (en) 6, 11-bridged biaryl macrolides
WO2007044927A3 (en) 6, 11-bridged tricyclic macrolides
WO2006065743A3 (en) Tetracylic bicyclolides
BR9708929A (en) Compound pharmaceutical composition and processes for controlling bacterial infection in a mammal and for preparing macrolide compounds
WO2003089446A3 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
WO2005067564A3 (en) 6-11 bicyclic erythromycin derivatives
CA2351829A1 (en) Macrolide antibiotics
WO2008014221A3 (en) Bridged carbamate macrolides

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190513